Log in

Relevant bibliographies by topics / HIPEC / Journal articles

To see the other types of publications on this topic, follow the link: HIPEC.

Journal articles on the topic 'HIPEC'

Author: Grafiati

Published: 4 June 2021

Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'HIPEC.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Tang, Qin, Mao Huang, Jing Zhang, et al. "Comparative Survival Outcomes of Hyperthermic Intraperitoneal Chemotherapy, Intraperitoneal Chemotherapy and Intravenous Chemotherapy for Primary Advanced Ovarian Cancer: A Network Meta-Analysis." Journal of Clinical Medicine 12, no. 3 (2023): 1111. http://dx.doi.org/10.3390/jcm12031111.

Full text

Abstract:

Objective: We aimed to compare the survival outcomes and adverse events of hyperthermic intraperitoneal chemotherapy (HIPEC), intraperitoneal chemotherapy (IP)and intravenous chemotherapy (IP)for primary advanced ovarian cancer. Methods: PubMed, CENTRAL (Cochrane Central Registry of Controlled Trials), Embase, Web of Science and Scopus were searched using multiple terms for primary advanced ovarian cancer, including randomized controlled trials and comparative studies in both Chinese and English (up to date 15 August 2022). Outcomes include overall survival, progression-free survival and adver

APA, Harvard, Vancouver, ISO, and other styles

2

Sood, Divya, Marie L. Fefferman, Natalie Marie Reizine, et al. "Impact of hyperthermic intraperitoneal chemotherapy on genomic heterogeneity of peritoneal metastases in stage IV gastroesophageal adenocarcinoma." Journal of Clinical Oncology 40, no. 4_suppl (2022): 312. http://dx.doi.org/10.1200/jco.2022.40.4_suppl.312.

Full text

Abstract:

312 Background: Programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) are potential biomarkers for response to therapy. Heterogeneity of PD-L1 and TMB has been demonstrated in gastroesophageal adenocarcinoma (GEA) in response to systemic chemotherapy. With the increased use of hyperthermic intraperitoneal chemotherapy (HIPEC) for GEA peritoneal metastases (PM), we aimed to determine the effects of HIPEC on genomic heterogeneity of PM. Methods: This is a retrospective review of a prospectively maintained database of patients with stage IV GEA who underwent iterative lap

APA, Harvard, Vancouver, ISO, and other styles

3

Pasqual, Enrico Maria, Ambrogio P. Londero, Manuela Robella, et al. "Repeated Cytoreduction Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Selected Patients Affected by Peritoneal Metastases: Italian PSM Oncoteam Evidence." Cancers 15, no. 3 (2023): 607. http://dx.doi.org/10.3390/cancers15030607.

Full text

Abstract:

The reiteration of surgical cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients affected by recurrent peritoneal metastases is still questioned regarding safety and effectiveness. This study evaluates the safety, efficacy, and associated factors of iterative CRS combined with HIPEC. This multicentric retrospective study collected data from four surgical oncology centers, on iterative HIPEC. We gathered data on patient and cancer characteristics, the peritoneal cancer index (PCI), completeness of cytoreduction (CC), postoperative complications, and overall surv

APA, Harvard, Vancouver, ISO, and other styles

4

Gareer, Waheed Yousry, Gamal Amira Mohamed, Mohamed H. Zedan, Tarek Sherif Al Baradei, Shaimaa Abdalaleem Abdalgeleel, and Sherif Mohamed Khairallah. "Predictors of Recurrence of Peritoneal Carcinomatosis among Patients with Colorectal Cancer Following Cytoreductive Surgery alone versus Cytoreductive Surgery Plus HIPEC." Journal of Coloproctology 42, no. 02 (2022): 107–14. http://dx.doi.org/10.1055/s-0041-1740472.

Full text

Abstract:

Abstract Background Peritoneal carcinomatosis (PC) is a lethal regional progression in patients with colorectal cancer (CRC). Treatment with complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) achieves better local control than systemic palliative chemotherapy. Objectives To assess the efficacy on the prognosis of CRS and HIPEC compared with CRS only and to identify possible clinicopathological factors associated with the recurrence of PC. Methods The present retrospective study included all colorectal carcinoma cases with PC subjected to CRS with or with

APA, Harvard, Vancouver, ISO, and other styles

5

Taub, Robert N., Joshua Leinwand, Gleneara Bates, et al. "In situ distribution of metallic platinum in tumor tissues after intraperitoneal platinum chemotherapy assessed by digital synchrotron-abetted x-ray fluorescence microscopy." Journal of Clinical Oncology 30, no. 15_suppl (2012): e13067-e13067. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e13067.

Full text

Abstract:

e13067 Background: Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) and catheter-administered intraperitoneal chemotherapy (CAIPEC) are used to treat peritoneal surface-spreading malignancies, including Malignant Peritoneal Mesothelioma (MPM), to maximize local drug concentrations. Previous HIPEC studies showed tissue penetration of cisplatin ~5mm from the peritoneal surface; biodistribution of CAIPEC has not been reported. Methods: Our protocol for MPM includes initial debulking surgery with HIPEC (41°C over 1 hour, drug is then removed), 6 cycles of CAIPEC (room temperature,

APA, Harvard, Vancouver, ISO, and other styles

6

Huber, Benjamin Michael. "Outcomes of patients with peritoneal carcinomatosis treated with HIPEC and chemotherapy or HIPEC alone: A single center community experience." Journal of Clinical Oncology 42, no. 16_suppl (2024): e15578-e15578. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e15578.

Full text

Abstract:

e15578 Background: Peritoneal carcinomatosis is a common presentation of intraperitoneal malignancies. The optimal management of peritoneal carcinomatosis is currently unknown but can contain a combination of HIPEC and chemotherapy. Optimal timing and order of these interventions is controversial. HIPEC surgery alone can provide a cure rate of approximately 16% with macroscopically complete resection. The PRODIGE 7 trial demonstrated no difference in overall survival between HIPEC plus cytoreduction versus cytoreduction alone with six months of systemic chemotherapy. Which patients should rece

APA, Harvard, Vancouver, ISO, and other styles

7

Ko, Jieun, Hyeong In Ha, Min Chul Choi, et al. "Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer." Obstetrics & Gynecology Science 64, no. 5 (2021): 437–43. http://dx.doi.org/10.5468/ogs.21093.

Full text

Abstract:

Objective To investigate the therapeutic efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) as consolidation treatment after completing first-line treatment in patients with advanced ovarian cancer.Methods A retrospective chart review was conducted on patients treated at the Comprehensive Gynecologic Cancer Center between January 2014 and 2019. Based on the inclusion criteria, 24 eligible patients who received HIPEC (paclitaxel 175 mg/m2, for 90 minutes, at 42°C) (HIPEC group) as consolidation treatment after terminating the adjuvant chemotherapy were identified. Another 24 patients

APA, Harvard, Vancouver, ISO, and other styles

8

White, Michael G., and Brian D. Badgwell. "Laparoscopic Heated Intraperitoneal Chemotherapy in the Treatment of Carcinomatosis of Gastric Adenocarcinoma Origin." Journal of Clinical Medicine 10, no. 20 (2021): 4757. http://dx.doi.org/10.3390/jcm10204757.

Full text

Abstract:

The use of heated intraperitoneal chemotherapy (HIPEC) in conjunction with cytoreductive surgery has been gaining increasing traction in treating gastric adenocarcinoma with metastasis to the peritoneum in recent years. The addition of laparoscopic HIPEC (LS-HIPEC) to these treatment algorithms has increased the flexibility and adaptability of HIPEC integrating into treatment sequencing, allowing for iterative protocols of LS-HIPEC prior to cytoreduction as neoadjuvant treatment, as well as in the palliation of patients with unresectable disease and uncontrolled ascites. As the use of HIPEC in

APA, Harvard, Vancouver, ISO, and other styles

9

Kireeva, Galina, Katran Guseynov, Georgiy Gafton, et al. "OPEN TECHNIQUE OF HYPERTHERMIC INTRAPERITONEAL CHEMOPERFUSION IN TREATMENT OF PERITONEAL CARCINOMATOSIS IN RATS WITH ASCITIC OVARIAN TUMOR." Problems in oncology 63, no. 5 (2017): 792–98. http://dx.doi.org/10.37469/0507-3758-2017-63-5-792-798.

Full text

Abstract:

For the first time comparative study of open and closed techniques of hyperthermic intraperitoneal chemoperfusion (HIPEC) in terms of safety and efficacy was performed in a rat model of ascetic ovarian cancer transplanted intraperitoneally. Original device and implantation technique of the device into peritoneal cavity were developed and used in the study. All animals after tumor implantation were randomized into 4 groups: 1 - control, intraperitoneal administration of 0.5 ml of saline (n=19); 2 - closed HIPEC with cisplatin, 20 mg/ kg (n=15); 3 - open HIPEC with cisplatin, 16 mg/kg (n=16); 4

APA, Harvard, Vancouver, ISO, and other styles

10

Dellinger, Thanh Hue, Xiwei Wu, Hyejin Cho, et al. "Whole transcriptome changes correlate to exceptional ovarian cancer responders: A sub-analysis of a HIPEC Phase I trial." Journal of Clinical Oncology 38, no. 15_suppl (2020): 6060. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6060.

Full text

Abstract:

6060 Background: Advanced stage ovarian cancer patients benefit from hyperthermic intraperitoneal chemotherapy (HIPEC), prolonging overall survival by nearly 12 months. However, molecular changes triggered by HIPEC are not well characterized, and no molecular signatures of response are known. We analyzed early gene expression changes after HIPEC treatment in ovarian tumors. Methods: This is an interval subgroup analysis of a single institution Phase I trial using HIPEC with cisplatin 75 mg/m2 at time of optimal cytoreduction. Snap-frozen biopsies from tumor and normal peritoneum from 20 patien

APA, Harvard, Vancouver, ISO, and other styles

11

Pereira, Fernando, Mónica Pereira, Israel Manzanedo, Ángel Serrano, and Estibalitz Pérez-Viejo. "Peritoneal Mesothelioma in a High Volume Peritoneal Surface Malignancies Unit." Journal of Clinical Medicine 12, no. 6 (2023): 2288. http://dx.doi.org/10.3390/jcm12062288.

Full text

Abstract:

Diffuse malignant peritoneal mesothelioma (PM) is a rare neoplasm, traditionally associated with a poor prognosis. There are other varieties of PM that are even less frequent and of uncertain malignancy. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has achieved prolonged survival in selected patients. The aim of this study is to analyze the patients with PM assessed in our center. Clinicopathological characteristics, diagnostic procedures and survival results from patients with PM appraised at our unit, according to the applied treatment, were analyzed. Se

APA, Harvard, Vancouver, ISO, and other styles

12

González Sánchez, Salud, Jorge García Fernández, Pedro Antonio Cascales-Campos, et al. "Interval Cytoreductive Surgery and Cisplatin- or Paclitaxel-Based HIPEC for Advanced Ovarian Cancer." JAMA Network Open 8, no. 6 (2025): e2517676. https://doi.org/10.1001/jamanetworkopen.2025.17676.

Full text

Abstract:

ImportanceOvarian cancer, often diagnosed at advanced stages, presents significant challenges in treatment and survival. Evaluation of different hyperthermic intraperitoneal chemotherapy (HIPEC) regimens could provide crucial insights to improve patient outcomes.ObjectiveTo evaluate whether HIPEC with paclitaxel (HIPEC-paclitaxel) is associated with similar oncological outcomes as HIPEC with cisplatin (HIPEC-cisplatin) in patients with advanced ovarian cancer undergoing interval cytoreductive surgery (iCRS).Design, Setting, and ParticipantsThis multicenter retrospective cohort study included p

APA, Harvard, Vancouver, ISO, and other styles

13

Abudeeb, Haytham, Chelliah R. Selvasekar, Sarah T. O’Dwyer, et al. "Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for perforated low-grade appendiceal mucinous neoplasms." Surgical Endoscopy 34, no. 12 (2020): 5516–21. http://dx.doi.org/10.1007/s00464-019-07349-x.

Full text

Abstract:

Abstract Introduction Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is an established treatment for pseudomyxoma peritonei (PMP) from perforated low-grade appendiceal mucinous neoplasms (LAMN II). In a selected group of LAMN II patients without established PMP, CRS/HIPEC can be performed laparoscopically (L-CRS/HIPEC); however the short-term benefits and safety of this approach have yet to be determined. This study aims to determine the short-term outcomes from a series of L-CRS/HIPEC LAMN II patients compared to those who have undergone a similar open operat

APA, Harvard, Vancouver, ISO, and other styles

14

D’Hondt, Véronique, Frédéric Goffin, Lise Roca, et al. "Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma: A Feasibility Study." International Journal of Gynecologic Cancer 26, no. 5 (2016): 912–17. http://dx.doi.org/10.1097/igc.0000000000000696.

Full text

Abstract:

ObjectivesWe conducted a phase 2 trial to assess the feasibility of interval cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in patients with stage III and IV pleural ovarian carcinoma in first-line treatment with no macroscopic residual disease after surgery.MethodsPatients could be treated either with primary CS with HIPEC followed by 6 conventional cycles of chemotherapy or with 3 or 4 cycles of neoadjuvant chemotherapy before CS with HIPEC and 3 postoperative chemotherapy cycles. Hyperthermic intraperitoneal chemotherapy was performed with ci

APA, Harvard, Vancouver, ISO, and other styles

15

Lim, Myong Cheol, Suk-Joon Chang, Heong Jong Yoo, Byung-Ho Nam, Robert Bristow, and Sang-Yoon Park. "Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer." Journal of Clinical Oncology 35, no. 15_suppl (2017): 5520. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5520.

Full text

Abstract:

5520 Background: Cytoreductive surgery followed by taxane and platinum-based chemotherapy is standard treatment for advanced ovarian cancer. We compared results of randomly allocated HIPEC in primary advanced epithelial ovarian cancer who have optimal cytoreductive surgery in this prospective randomized multicenter trial. The study endpoint is to evaluate progression free survival (PFS) and overall survival (OS). Methods: 184 patients staged III and IV were randomly allocated to trial arm (HIPEC, cisplatin 75 mg/m2, 90 min) or control arm (no HIPEC), intraoperatively based on residual tumor (s

APA, Harvard, Vancouver, ISO, and other styles

16

Panja, Asit B., Prerona Panja, Rachana Bhatt, and Ansamma Joseph. "Expression and regulation of chemokine receptor CXCR3 (CD183) on human gastrointestinal stem cells (hGISC) derived primary epithelial cells." Journal of Immunology 198, no. 1_Supplement (2017): 55.47. http://dx.doi.org/10.4049/jimmunol.198.supp.55.47.

Full text

Abstract:

Abstract Expression of Chemokine receptor CXCR3 (CD183) by cells in inflamed tissues play essential role in the development of chronic conditions by attracting leucocytes to the inflammatory sites. CXCR3 expression in intestinal epithelium has also been implicated in celiac disease by means of its potential role in peptide (gliadin) uptake and triggering of immune responses in the small intestine. Therefore, having an CXCR3 expressing intestinal epithelial cell system in long-term culture would be a valuable tool for discovery and development of new treatments for celiac and/or other gastroint

APA, Harvard, Vancouver, ISO, and other styles

17

Sun, Beatrice J., Sara K. Daniel, and Byrne Lee. "The Role of Prophylactic and Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Prevention of Peritoneal Metastases in Advanced Colorectal Cancer." Journal of Clinical Medicine 12, no. 20 (2023): 6443. http://dx.doi.org/10.3390/jcm12206443.

Full text

Abstract:

Hyperthermic intraperitoneal chemotherapy (HIPEC) is a locoregional therapy that may be combined with cytoreductive surgery (CRS) to treat patients with colorectal cancer and peritoneal metastases (PM). In recent years, three randomized controlled trials (RCTs) have investigated the role of prophylactic or adjuvant HIPEC in preventing the development of PM in patients with high-risk colorectal cancer: PROPHYLOCHIP and COLOPEC evaluated adjuvant HIPEC, and HIPECT4 studied concurrent HIPEC and CRS. Although PROPHYLOCHIP and COLOPEC were negative trials, a great deal may be learned from their met

APA, Harvard, Vancouver, ISO, and other styles

18

Karpes, Josh, Roneil Parikh, Raphael Shamavonian, Nayef Alzahrani, and David L. Morris. "Analysis of feasibility and survival in repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in appendiceal cancer with peritoneal dissemination." Journal of Clinical Oncology 37, no. 15_suppl (2019): e15702-e15702. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e15702.

Full text

Abstract:

e15702 Background: CRS/HIPEC has been established as the method of choice for the management of peritoneal dissemination from appendiceal cancer. With recurrence rates after first surgery as high as 44%, re-do CRS/HIPEC is evolving as an effective recurrent treatment regime. This analysis examines the feasibility of repeated CRS/HIPEC for patients with appendiceal cancer with peritoneal dissemination and evaluates the survival outcomes. Methods: A retrospective cohort study of 1074 patients who had CRS/HIPEC procedures and had a recorded tumour grade from 1996 to 2017 was performed. Morbidity

APA, Harvard, Vancouver, ISO, and other styles

19

Moon, Jiae, Young Chul Yoo, Myoung Hwa Kim, et al. "Administration of Low-Dose Dexmedetomidine Did Not Affect Acute Inflammatory Response after Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy: A Double-Blind Randomized Controlled Trial." Journal of Clinical Medicine 10, no. 14 (2021): 3145. http://dx.doi.org/10.3390/jcm10143145.

Full text

Abstract:

During cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), attenuation of inflammatory responses that increase susceptibility to postoperative complications, morbidity, and mortality is important. We aimed to evaluate whether intraoperative dexmedetomidine infusion impacted inflammatory response in patients undergoing CRS with HIPEC. Fifty-six patients scheduled for CRS with HIPEC were randomly assigned to the control (n = 28) and dexmedetomidine (n = 28) groups. The primary endpoint was the effect of dexmedetomidine on the interleukin-6 (IL-6) level measured at

APA, Harvard, Vancouver, ISO, and other styles

20

Villarejo Campos, Pedro, Susana Sánchez García, Mariano Amo-Salas, et al. "Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA)." Current Oncology 31, no. 2 (2024): 660–71. http://dx.doi.org/10.3390/curroncol31020048.

Full text

Abstract:

Multidisciplinary strategies have transformed the management of advanced ovarian cancer. We aimed to evaluate the effectiveness of paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) following surgical cytoreduction for ovarian peritoneal metastases in a randomized phase III trial conducted between August 2012 and December 2019. Seventy-six patients were randomized to either the HIPEC or no HIPEC group. Although median values for the primary endpoints (recurrence-free survival (RFS) and overall survival (OS)) revealed superior outcomes for the HIPEC (RFS: 23 months, OS: 48 months)

APA, Harvard, Vancouver, ISO, and other styles

21

Kireeva, Galina, Stepan Kruglov, Mikhail Maydin, et al. "Modeling of Chemoperfusion vs. Intravenous Administration of Cisplatin in Wistar Rats: Adsorption and Tissue Distribution." Molecules 25, no. 20 (2020): 4733. http://dx.doi.org/10.3390/molecules25204733.

Full text

Abstract:

Hyperthermic intraperitoneal chemoperfusion (HIPEC) is an established form of locoregional chemotherapy of peritoneum tumors. However, its efficacy and safety status remain a controversy, partially, due to scarce data on pharmacokinetics and toxicity profile of drugs under HIPEC. In the current study, 24 female Wistar rats were randomly assigned to receive cisplatin as HIPEC (n = 12, 20 mg/kg) or intravenously (i.v., n = 9, 4 mg/kg). The subgroups of three animals were used for the initial, intermediate, and late phases of the pharmacokinetic assessment. The animals were sacrificed on days 1 a

APA, Harvard, Vancouver, ISO, and other styles

22

Bhatt, Aditi, and Olivier Glehen. "Hyperthermic Intraperitoneal Chemotherapy in the Treatment Armamentarium of Epithelial Ovarian Cancer: Time to End the Dichotomy." Visceral Medicine 38, no. 2 (2022): 109–19. http://dx.doi.org/10.1159/000521239.

Full text

Abstract:

<b><i>Background:</i></b> Advanced epithelial ovarian cancer (EOC) is an incurable disease with over 75% of the patients developing recurrence in the peritoneum. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising treatment option for both first-line therapy and treatment of recurrence. In this article, we review the rationale and current evidence for performing HIPEC and the role of HIPEC in the light of targeted systemic therapies. <b><i>Summary:</i></b> There are few randomized trials and several retrospective studies on the role

APA, Harvard, Vancouver, ISO, and other styles

23

Acs, Miklos, Zoltan Herold, Attila Marcell Szasz, Max Mayr, Sebastian Häusler, and Pompiliu Piso. "Prolonged Exposition with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) May Provide Survival Benefit after Cytoreductive Surgery (CRS) in Advanced Primary Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer." Cancers 14, no. 14 (2022): 3301. http://dx.doi.org/10.3390/cancers14143301.

Full text

Abstract:

Background: The usage of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gynecological cancers is increasing. Methods: Prospectively collected data of 85 advanced primary ovarian/fallopian tube cancer and peritoneal carcinoma patients of a single center were investigated. Results: A total 48, 37, 62, and 25 patients were enrolled into the HIPEC with/without neoadjuvant chemotherapy (upfront vs. interval) and into the 60 min and 90 min long HIPEC groups, respectively. Better overall survival (OS) was observed in the 90 min HIPEC group (p = 0.03

APA, Harvard, Vancouver, ISO, and other styles

24

Hanna, David N., Muhammad O. Ghani, Andrew Hermina, et al. "Diagnostic Laparoscopy in Patients With Peritoneal Carcinomatosis Is Safe and Does Not Delay Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy." American Surgeon 88, no. 4 (2021): 698–703. http://dx.doi.org/10.1177/00031348211048819.

Full text

Abstract:

Background Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) among patients with peritoneal carcinomatosis (PC) depend largely on the extent of peritoneal disease. Since PC is not reliably evaluated with cross-sectional imaging, tumor burden is often evaluated with diagnostic laparoscopy (DLS). The aims of this study are to evaluate the safety of DLS in patients with peritoneal disease and determine if DLS delays time to CRS-HIPEC. Methods We performed an institutional retrospective review of 145 patients who underwent CRS-HIPEC between 2013 and 2020.

APA, Harvard, Vancouver, ISO, and other styles

25

Fleming, Andrew M., Owen M. Clark, Jaewon J. Lee, et al. "Iterative Cytoreductive Surgery and HIPEC for Peritoneal Metastases from Primary Appendiceal and Colorectal Cancers: An Observational Study." Cancers 17, no. 12 (2025): 2014. https://doi.org/10.3390/cancers17122014.

Full text

Abstract:

Background: Peritoneal relapse after cytoreduction and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is common. Repeat CRS/HIPEC offers the potential for long-term survival in the appropriately selected patient. Methods: We performed a retrospective review of a single institution database to assess perioperative outcomes after repeat CRS/HIPEC for appendiceal (pAC) and colorectal (pCRC) cancers. Kaplan–Meier and Cox estimates were used to assess survival. Results: Of 157 patients, 103 patients underwent initial CRS/HIPEC for pAC (n = 67) or pCRC (n = 36) histologies. Twenty-seven pAC p

APA, Harvard, Vancouver, ISO, and other styles

26

Zivanovic, Oliver, Dennis S. Chi, Qin Zhou, et al. "Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study." Journal of Clinical Oncology 39, no. 23 (2021): 2594–604. http://dx.doi.org/10.1200/jco.21.00605.

Full text

Abstract:

PURPOSE The purpose of this phase II study was to evaluate hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin for recurrent ovarian cancer during secondary cytoreductive surgery. MATERIALS AND METHODS Patients were intraoperatively randomly assigned to carboplatin HIPEC (800 mg/m2 for 90 minutes) or no HIPEC, followed by five or six cycles of postoperative IV carboplatin-based chemotherapy, respectively. Based on a binomial single-stage pick-the-winner design, an arm was considered winner if ≥ 17 of 49 patients were without disease progression at 24 months post-surgery. Seconda

APA, Harvard, Vancouver, ISO, and other styles

27

Quenet, François, Dominique Elias, Lise Roca, et al. "A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7." Journal of Clinical Oncology 36, no. 18_suppl (2018): LBA3503. http://dx.doi.org/10.1200/jco.2018.36.18_suppl.lba3503.

Full text

Abstract:

LBA3503 Background: Promising results have been obtained during the last decade using cytoreductive surgery (CRS) plus HIPEC for selected patients with colorectal PC who are amenable to complete macroscopic resection. This is the first trial to evaluate the specific role of HIPEC, after CRS, for the treatment of PC of colorectal origin. Methods: Prodige 7 is a randomized phase III, multicenter trial. Patients with histologically proven and isolated PC, peritoneal cancer index (PCI) ≤25 were eligible. Randomization (1:1) was stratified by center, complete macroscopic resection (R0/1 vs R2), and

APA, Harvard, Vancouver, ISO, and other styles

28

Gronau, Felix, Linda Feldbruegge, Frauke Oberwittler, et al. "HIPEC in Peritoneal Metastasis of Gastric Origin: A Systematic Review of Regimens and Techniques." Journal of Clinical Medicine 11, no. 5 (2022): 1456. http://dx.doi.org/10.3390/jcm11051456.

Full text

Abstract:

(1) Background: Peritoneal metastasis in gastric cancer is associated with a poor prognosis. Complete cytoreductive surgery including gastrectomy and complete removal of all peritoneal lesions followed by hyperthermic intraperitoneal chemotherapy (HIPEC) achieves promising results. There exists an immersive variety of approaches for HIPEC that makes it difficult to weigh different results obtained in the literature. In order to enable standardization and development of HIPEC, we here present a systematic review of different drug regimens and technical approaches. (2) Methods: PubMed, Embase, a

APA, Harvard, Vancouver, ISO, and other styles

29

Jelenek, Gabriel, Libor Němec, Magdalena Plch, and Jana Kalvodová. "HIPEC - ovarian cancer case report." Onkologie 18, no. 5 (2024): 311–14. http://dx.doi.org/10.36290/xon.2024.064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Zivanovic, Oliver, Dennis Chi, Qin Zhou, et al. "A randomized phase II trial of secondary cytoreductive surgery (SCS) +/- carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) in patients (pts) with recurrent platinum-sensitive ovarian cancer (EOC)." Journal of Clinical Oncology 38, no. 15_suppl (2020): 6016. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6016.

Full text

Abstract:

6016 Background: The role of HIPEC for recurrent EOC is not well defined. The aim of this phase II study was to determine the proportion of pts without evidence of disease progression at 24 months post SCS +/- intraoperative carboplatin HIPEC. Methods: After SCS to ≤ 0.5 cm residual visible disease pts were intraoperatively randomized to carboplatin HIPEC (800mg/m2 for 90 minutes) or no HIPEC. The HIPEC arm received 5 additional and the standard arm received 6 postoperative cycles of IV platinum-based chemotherapy without maintenance treatment. Based on an exact binomial single stage “pick the

APA, Harvard, Vancouver, ISO, and other styles

31

Mendivil, Alberto, Lisa Nicole Abaid, John V. Brown, Kristina Mori, Katrina Lopez, and Bram Goldstein. "Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: A 3-year experience." Journal of Clinical Oncology 35, no. 15_suppl (2017): e17094-e17094. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e17094.

Full text

Abstract:

e17094 Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) potentially confers significant survival benefits in the management of ovarian cancer although the long-term data remain scant. We sought to compare the survival rates of advanced stage ovarian cancer patients who were treated with primary induction therapy alone or in conjunction with consolidation HIPEC. Methods: Sixty-nine ovarian cancer patients who underwent surgery and completed their primary induction chemotherapy were treated with consolidation carboplatin (AUC 10) based HIPEC and compared to a historical cohort that

APA, Harvard, Vancouver, ISO, and other styles

32

Tsolakidis, Dimitrios, Dimitrios Kyziridis, Theodoros Panoskaltsis, et al. "Evaluating the Impact of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on Interval and Secondary Debulking in Ovarian Cancer: A Systematic Review." Cancers 17, no. 5 (2025): 904. https://doi.org/10.3390/cancers17050904.

Full text

Abstract:

Background/Objectives: Hyperthermic intraperitoneal chemotherapy (HIPEC) was revealed as a promising adjunct to cytoreductive surgery (CRS) in the treatment of advanced epithelial ovarian cancer (EOC). This review evaluated the impact HIPEC had on survival outcomes, recurrence patterns and safety in patients that underwent HIPEC in conjunction with interval and secondary CRS for advanced and recurrent ovarian cancer. Methods: A thorough search was conducted using PubMed, Scopus, Cochrane Library, and Google Scholar to identify relevant studies published until 1 January 2025. The studies were a

APA, Harvard, Vancouver, ISO, and other styles

33

Yurttas, Can, Giulia Hoffmann, Alexander Tolios, et al. "Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer." Journal of Clinical Medicine 7, no. 12 (2018): 567. http://dx.doi.org/10.3390/jcm7120567.

Full text

Abstract:

Cytoreductive surgery (CRS), followed by hyperthermic intraperitoneal chemotherapy (HIPEC), combines radical surgery with abdominal heated chemotherapy, constituting a multimodal treatment approach. Since clear standards for HIPEC conduct in colorectal carcinoma (CRC) are lacking, we aimed to provide a comprehensive structured survey. Data sources and study eligibility criteria: A systematic literature search was performed in PubMed, with keywords “HIPEC” and “colorectal cancer”, according to established guidelines. Articles were systematically screened, selecting 87 publications complemented

APA, Harvard, Vancouver, ISO, and other styles

34

Tinsley, Nadina, Raghavendar Nagaraju, Sarah O'Dwyer, et al. "Cytoreductive surgery and HIPEC in colorectal cancer peritoneal metastases (CRPM): Real-world outcomes in systemic anticancer treatment–naïve patients." Journal of Clinical Oncology 41, no. 4_suppl (2023): 39. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.39.

Full text

Abstract:

39 Background: The role of heated intraperitoneal chemotherapy (HIPEC) in colorectal cancer peritoneal metastases (CRPM) is confounded by cytoreductive surgery (CRS) or receipt of peri-operative systemic anticancer therapy (SACT). Following Prodige-7, the role of Oxaliplatin HIPEC in addition to CRS has been debated. We evaluated a patient series undergoing CRS with Oxaliplatin (368mg/m2 for 30 mins) or Mitomycin C (MMC) (35mg/m2 for 90 mins) HIPEC stratified by extent of CRS and SACT. Methods: Data collected retrospectively from a prospective database of CRPM patients undergoing CRS +/- HIPEC

APA, Harvard, Vancouver, ISO, and other styles

35

A. A, Tentes, Kyziridis D., Kalakonas A, and Karanikiotis H. "Outcomes of Locally Advanced Gastric Cancer Treated with D2 Gastrectomy and HIPEC." International Journal of Medical Science and Health Research 09, no. 01 (2025): 47–63. https://doi.org/10.51505/ijmshr.2025.9104.

Full text

Abstract:

D2 gastrectomy followed by adjuvant chemotherapy is considered the potentially curative treatment for locally advanced gastric cancer. The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising adjuvant treatment intending to reduce the incidence of loco-regional recurrences. The aim of the study is to evaluate the effect of HIPEC in locally advanced gastric cancer by comparing patients who underwent D2 gastrectomy and HIPEC (HIPEC group) with D2 gastrectomy alone (CON group).

APA, Harvard, Vancouver, ISO, and other styles

36

Dellinger, Thanh Hue, Xiwei Wu, Hyejin Cho, et al. "Association of HIPEC response in ovarian cancer with PI3K/RAS/Notch gene signatures: A whole transcriptomic analysis of U.S. and French HIPEC treated ovarian cancer patients." Journal of Clinical Oncology 43, no. 16_suppl (2025): 5569. https://doi.org/10.1200/jco.2025.43.16_suppl.5569.

Full text

Abstract:

5569 Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with improved overall survival in Stage III epithelial ovarian cancer (EOC) patients. We set out to evaluate the gene signatures associated with HIPEC response in EOC patients. Methods: Ninety-one EOC patients who underwent HIPEC with pre-operative tumor samples at City of Hope (51) and CHU Lyon (40) were identified between 2014 and 2022. RNA isolation was performed from formalin-fixed paraffin-embedded samples, followed by Whole-transcriptome library construction. Following exclusion of non-high grade serous (HGS

APA, Harvard, Vancouver, ISO, and other styles

37

Steffen, Thomas, Lukas Häller, Lana Bijelic, et al. "Decision-Making Analysis for Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: A Survey by the Executive Committee of the Peritoneal Surface Oncology Group International (PSOGI)." Oncology 99, no. 1 (2020): 41–48. http://dx.doi.org/10.1159/000510098.

Full text

Abstract:

<b><i>Objectives:</i></b> To assess the individual treatment strategies among international experts in peritoneal carcinosis, specifically their decision-making in the process of patient selection for hyperthermic intraperitoneal chemotherapy (HIPEC) in women suffering from ovarian cancer, to identify relevant decision-making criteria, and to quantify the level of consensus for or against HIPEC. <b><i>Methods:</i></b> The members of the executive committee of the Peritoneal Surface Oncology Group International (PSOGI) were asked to describe the c

APA, Harvard, Vancouver, ISO, and other styles

38

Seyfried, Nick, Can Yurttas, Markus Burkard, et al. "Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model." Cancers 14, no. 5 (2022): 1158. http://dx.doi.org/10.3390/cancers14051158.

Full text

Abstract:

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) was considered a promising treatment for patients with peritoneal metastasis from colorectal cancer. However, the recently published randomized controlled PRODIGE 7 trial failed to demonstrate survival benefits through the addition of short-term oxaliplatin-based HIPEC. Constituting a complex multifactorial treatment, we investigated HIPEC in a preclinical model concerning the elimination of minimal tumor residues, thereby aiming to better understand the size of effects and respective clinical trial results.

APA, Harvard, Vancouver, ISO, and other styles

39

Yurttas, Can, Oliver M. Fisher, Delia Cortés-Guiral, et al. "Cytoreductive surgery and HIPEC in colorectal cancer—did we get hold of the wrong end of the stick?" memo - Magazine of European Medical Oncology 13, no. 4 (2020): 434–39. http://dx.doi.org/10.1007/s12254-020-00653-6.

Full text

Abstract:

SummaryCytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are a multimodal treatment approach combining surgical interventions of varying extent with administration of heated cytostatic drugs flushed through the abdominal cavity. Hitherto, this treatment has been popular for peritoneal metastasis (PM), e.g. from colorectal cancer (CRC). Recent randomized controlled trials (RCT) question the benefit of HIPEC in its present form for CRC treatment and raise fundamental issues, eliciting discussions and expert statements regarding HIPEC relevance and interpretation o

APA, Harvard, Vancouver, ISO, and other styles

40

Ghanipour, Lana, Gabriella Jansson Palmer, Per J. Nilsson, et al. "Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol." PLOS ONE 19, no. 3 (2024): e0294018. http://dx.doi.org/10.1371/journal.pone.0294018.

Full text

Abstract:

Standard treatment for patient with peritoneal metastases from colorectal cancer is cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). In recent years, the efficacy of oxaliplatin-based HIPEC has been challenged. An intensified HIPEC (oxaliplatin+irinotecan) in combination with early postoperative intraperitoneal chemotherapy (EPIC) has shown increased recurrence-free survival in retrospective studies. The aim of this trial is to develop a new HIPEC/EPIC regimen and evaluate its effect on morbidity, oncological outcome, and quality-of-life (QoL). This study is d

APA, Harvard, Vancouver, ISO, and other styles

41

Taqi, Kadhim, Jay Lee, Scott Hurton, et al. "Long-Term Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin." Current Oncology 31, no. 7 (2024): 3657–68. http://dx.doi.org/10.3390/curroncol31070269.

Full text

Abstract:

Background: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a major treatment of colorectal peritoneal carcinomatosis (CPC). The aim was to determine the disease-free survival (DFS) and overall survival (OS) of patients undergoing CRS–HIPEC for CPC and factors associated with long-term survival (LTS). Methods: consecutive CPC patients who underwent CRS–HIPEC at a HIPEC center between 2007 and 2021 were included. Actual survival was calculated, and Cox proportional hazards models were used to identify factors associated with OS, DFS and LTS. Result

APA, Harvard, Vancouver, ISO, and other styles

42

van Leeuwen, B. L., W. Graf, L. Pahlman, and H. Mahteme. "Swedish Experience with Peritonectomy and HIPEC. HIPEC in Peritoneal Carcinomatosis." Annals of Surgical Oncology 15, no. 3 (2007): 745–53. http://dx.doi.org/10.1245/s10434-007-9700-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Ryan, David P. "To HIPEC or Not to HIPEC? That Is The Question." Current Colorectal Cancer Reports 10, no. 3 (2014): 251–53. http://dx.doi.org/10.1007/s11888-014-0236-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Kumar C, Rohit, Somashekhar S. P, Ashwin K. R, et al. "Bowel Anastomosis In Cytoreductive Surgery + HIPEC: After Or Before HIPEC." International Journal of Gynecological Cancer 35, no. 2 (2025): 100291. https://doi.org/10.1016/j.ijgc.2024.100291.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Kim, Myoung Hwa, Young Chul Yoo, Sun Joon Bai, Kang-Young Lee, Nayeon Kim, and Ki Young Lee. "Physiologic and hemodynamic changes in patients undergoing open abdominal cytoreductive surgery with hyperthermic intraperitoneal chemotherapy." Journal of International Medical Research 49, no. 1 (2021): 030006052098326. http://dx.doi.org/10.1177/0300060520983263.

Full text

Abstract:

Objective We aimed to determine the physiological and hemodynamic changes in patients who were undergoing hyperthermic intraperitoneal chemotherapy (HIPEC) cytoreductive surgeries. Methods This prospective, observational study enrolled 21 patients who were undergoing elective cytoreductive surgery with HIPEC at our hospital over 2 years. We collected vital signs, hemodynamic parameters including global end-diastolic volume index (GEVI) and extravascular lung water index (ELWI) using the VolumeView™ system, and arterial blood gas analysis from all patients. Data were recorded before skin incisi

APA, Harvard, Vancouver, ISO, and other styles

46

Brenkman, H. J. F., M. Päeva, R. van Hillegersberg, J. P. Ruurda, and N. Haj Mohammad. "Prophylactic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer—A Systematic Review." Journal of Clinical Medicine 8, no. 10 (2019): 1685. http://dx.doi.org/10.3390/jcm8101685.

Full text

Abstract:

Survival after potentially curative treatment of gastric cancer remains low, mostly due to peritoneal recurrence. This descriptive review gives an overview of available comparative studies concerning prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with gastric cancer with neither clinically evident metastases nor positive peritoneal cytology who undergo potentially curative gastrectomy. After searching the PubMed, Embase, CDSR, CENTRAL and ASCO meeting library, a total of 11 studies were included comparing surgery plus prophylactic HIPEC versus surgery alone (SA): t

APA, Harvard, Vancouver, ISO, and other styles

47

Martin, Carla A., and Asit Panja. "Cytokine regulation of human intestinal primary epithelial cell susceptibility to Fas-mediated apoptosis." American Journal of Physiology-Gastrointestinal and Liver Physiology 282, no. 1 (2002): G92—G104. http://dx.doi.org/10.1152/ajpgi.2002.282.1.g92.

Full text

Abstract:

The regulatory mechanisms of nontransformed intestinal epithelial cell apoptosis have not been thoroughly investigated. We determined the susceptibility and mechanism of Fas-mediated apoptosis in nontransformed human intestinal epithelial cells (HIPEC) in the presence and absence of inflammatory cytokines. Despite ample expression of Fas, HIPEC were relatively insensitive to Fas-mediated apoptosis in that agonist anti-Fas antibody (CH11) induced a <25% increase in HIPEC apoptosis. Pretreatment of HIPEC with interferon (IFN)-γ, but not tumor necrosis factor-α or granulocyte-macrophage colony

APA, Harvard, Vancouver, ISO, and other styles

48

Cerit Karadeniz, Kıvılcım, Nurşah Eker, Ahsen Karagözlü Akgül, et al. "Does cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improve survival in children with desmoplastic small round cell tumors? First experiences from Turkey." Marmara Medical Journal 38, no. 1 (2025): 29–35. https://doi.org/10.5472/marumj.1627763.

Full text

Abstract:

Objective: Desmoplastic small round cell tumor (DSRCT) is a rare form of highly aggressive sarcoma and despite multimodal therapy, mortality still remains high. The aim of the study is to review our experience in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in children with DSRCT. Patients and Methods: A retrospective review of patients with DSRCT followed in our institution between January 2020-January 2024 was performed. Demographics, radiological imaging, histopathology results, cytogenetic analyses, chemotherapy/radiotherapy protocols, operative data an

APA, Harvard, Vancouver, ISO, and other styles

49

Glockzin, Gabriel, Michael Gerken, Sven A. Lang, Hans J. Schlitt, and Pompiliu Piso. "Comparison of two bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) regimens in patients with colorectal peritoneal metastasis." Journal of Clinical Oncology 32, no. 3_suppl (2014): 628. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.628.

Full text

Abstract:

628 Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) became part of many national and international treatment guidelines as an additive therapeutic option for selected patients with colorectal peritoneal metastasis. Multiple HIPEC regimens are used regarding cytotoxic agents, concentration, perfusion time an other parameters and consistent data for standardization is missing. Methods: 32 consecutive patients after complete macroscopic cytoreduction (CC-0/1) and bidirectional HIPEC for colorectal peritoneal metastasis were retrospectively analyzed. T

APA, Harvard, Vancouver, ISO, and other styles

50

Guo, Xikai, Yao Lin, Chu Shen, et al. "Comparative Study of Short-Term Efficacy and Safety of Radical Surgery with or without Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancer with T4 Stage: A Propensity Score Matching Analysis." Journal of Clinical Medicine 12, no. 3 (2023): 1145. http://dx.doi.org/10.3390/jcm12031145.

Full text

Abstract:

Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) in T4 colorectal cancer (CRC) remains controversial. The study aimed to explore the safety and efficacy of radical surgery (RS) with HIPEC in T4 CRC. Methods: Adverse events after HIPEC were estimated by Common Terminology Criteria for Adverse Events version 5.0. The efficacy was evaluated using recurrence-free survival (RFS) and overall survival (OS). Propensity score matching (PSM) was used to reduce the effects of confounders between groups. Results: Of the 417 patients (263 men and 154 women), 165 patients were treated with RS +

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!